HighTower Advisors
AVDL

HighTower Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

HighTower Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,400
Closed -$6.38K – 3757
2024
Q4 		$6.38K Sell
4,400
-400
-8% -$4.86K ﹤0.01% 3616
2024
Q3 		$11.6K Buy
+4,800
New +$73.1K ﹤0.01% 3540

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

HighTower Advisors's AVDL Position: Q1 2026 in Review

HighTower Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 15,209 shares — an estimated $328K sold.

HighTower Advisors first reported a position in AVDL in Q3 2024 and held it in 4 quarters. The position peaked at $328K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • HighTower Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HighTower Advisors sold 15,209 Avadel Pharmaceuticals shares in Q1 2026, an estimated $328K.
  • HighTower Advisors first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • HighTower Advisors's Avadel Pharmaceuticals position peaked at $328K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.